Advanced Lung Cancer Clinical Trial
Official title:
A Single Arm, Open-label, Multicenter, Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer Patients
This Ib / IIa clinical trial program focuses on the small cell lung cancer (SCLC), Squamous non-small cell lung cancer (NSCLC) and adeniform NSCLC in order to start a better development on the broad-spectrum value of chlorogenic acid： Determine the Disease control rate（DCR）of phase Ib/IIa of Chlorogenic acid for injection in the advanced Lung Cancer Patients.
1. Determine the Disease control rate（DCR）of Chlorogenic acid for injection in the advanced
Lung Cancer Patients;
2. Determine the Overall Survival（OS）of Chlorogenic acid for injection in the advanced Lung
Cancer Patients;
3. Determine the Objective response rate（ORR）of Chlorogenic acid for injection in the
advanced Lung Cancer Patients;
4. Determine the Progression Free Survival（PFS）of Chlorogenic acid for injection in the
advanced Lung Cancer Patients;
5. Determine Eastern Cooperative Oncology Group（ECOG）.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04575831 -
Exercise, Nutrition, and Palliative Care in Advanced Lung Cancer (ENPAL)
|
N/A | |
| Completed |
NCT04069494 -
Descriptors and Predictors of Burden and Information Needs
|
||
| Terminated |
NCT03330834 -
CAR-T Cell Immunotherapy for Advanced Lung Cancer
|
Phase 1 | |
| Withdrawn |
NCT03004105 -
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Withdrawn |
NCT03501056 -
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05279521 -
The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer.
|
N/A | |
| Terminated |
NCT02768337 -
Cambridge Brain Mets Trial 1
|
Phase 1/Phase 2 | |
| Completed |
NCT04672369 -
A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC
|
Phase 1 | |
| Not yet recruiting |
NCT05431569 -
A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06456138 -
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06228209 -
Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer
|
N/A | |
| Completed |
NCT04672356 -
A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT04670445 -
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
|
N/A | |
| Not yet recruiting |
NCT06107894 -
TIL Therapy for Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06183762 -
A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
|
||
| Recruiting |
NCT05664971 -
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05815862 -
Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer
|
Phase 2 | |
| Recruiting |
NCT05805956 -
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06106152 -
WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody
|
Early Phase 1 | |
| Recruiting |
NCT05000684 -
Study of JS004 Combined With Toripalimab for Advanced Lung Cancer
|
Phase 1/Phase 2 |